Frontier Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Frontier Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200,653	Closed	-$5.53M	–	278
2023 Q3	$5.53M	Sell	200,653 -2,000	-1%	-$60.9K	0.06%	225
2023 Q2	$6.09M	Sell	202,653 -102,426	-34%	-$3.58M	0.06%	226
2023 Q1	$11.1M	Sell	305,079 -350,653	-53%	-$13.5M	0.11%	187
2022 Q4	$23.4M	Sell	655,732 -47,076	-7%	-$1.64M	0.25%	145
2022 Q3	$23.8M	Buy	702,808 +86,433	+14%	+$2.81M	0.28%	130
2022 Q2	$17.8M	Sell	616,375 -34,980	-5%	-$1M	0.21%	157
2022 Q1	$21.1M	Buy	651,355 +33,654	+5%	+$1.03M	0.19%	165
2021 Q4	$18M	Buy	617,701 +38,628	+7%	+$1.17M	0.14%	182
2021 Q3	$15.4M	Sell	579,073 -237,658	-29%	-$6.38M	0.12%	191
2021 Q2	$25.1M	Buy	816,731 +47,208	+6%	+$1.45M	0.18%	170
2021 Q1	$20.1M	Buy	+769,523	New	+$21.5M	0.15%	170

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Frontier Capital Management's SUPN Position: Q4 2023 in Review

Frontier Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2023, closing a stake of 200,653 shares — an estimated $5.53M sold.

Frontier Capital Management first reported a position in SUPN in Q1 2021 and held it in 11 quarters. The position peaked at $25.1M in Q2 2021. 246 funds tracked by Wall St. Rank hold SUPN as of Q4 2023.

Frontier Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Frontier Capital Management sold 200,653 Supernus Pharmaceuticals shares in Q4 2023, an estimated $5.53M.
Frontier Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 11 quarters.
Frontier Capital Management's Supernus Pharmaceuticals position peaked at $25.1M in Q2 2021.
246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2023.

Based on Frontier Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.